Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 5011-5017

  Yang, Y Q ^a   Chen, J ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Predictive factors; Prognosis; Renal cell carcinoma; VEGF polymorphism

Indexed keywords

ADENINE; CYTOSINE; GUANINE; VASCULOTROPIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHILIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTE COUNT; VEGF GENE; AGED; CARCINOMA, RENAL CELL; CELL COUNT; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; KIDNEY NEOPLASMS; LYMPHOCYTE; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROMOTER REGION; SURVIVAL; THROMBOCYTE;

ADULT; AGED; BLOOD PLATELETS; CARCINOMA, RENAL CELL; CELL COUNT; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903974405     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.July.4.16     Document Type: Article

References (21)

1. Absenger G, Szkandera J, Stotz M, Pichler M, et al. (2013). A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol. Carcinog. 52 (Suppl 1): E96-E102.
2. Choueiri TK, Bukowski RM and Rini BI (2006). The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin. Oncol. 33: 596-606.
3. Hefler LA, Mustea A, Konsgen D, Concin N, et al. (2007). Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin. Cancer Res. 13: 898-901.
4. Heng DY, Xie W, Regan MM, Warren MA, et al. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27: 5794-5799.
5. Hollen CW, Henthorn J, Koziol JA and Burstein SA (1992). Serum interleukin-6 levels in patients with thrombocytosis. Leuk. Lymphoma 8: 235-241.
6. Hollingsworth JM, Miller DC, Daignault S and Hollenbeck BK (2006). Rising incidence of small renal masses: a need to reassess treatment effect. J. Natl. Cancer Inst. 98: 1331-1334.
7. Jäkel CE, Hauser S, Rogenhofer S, Müller SC, et al. (2012). Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin. Dev. Immunol. 2012: 473245.
8. Kawai Y, Sakano S, Korenaga Y, Eguchi S, et al. (2007). Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur. Urol. 52: 1147-1155.
9. Langsenlehner T, Langsenlehner U, Renner W, Krippl P, et al. (2008). Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur. J. Cancer 44: 1572-1576.
10. Mathew A, Devesa SS, Fraumeni JF Jr and Chow WH (2002). Global increases in kidney cancer incidence, 1973-1992. Eur. J. Cancer Prev. 11: 171-178.
11. Mohle R, Green D, Moore MA, Nachman RL, et al. (1997). Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. U. S. A. 94: 663-668.
12. Motzer RJ, Bander NH and Nanus DM (1996). Renal-cell carcinoma. N. Engl. J. Med. 335: 865-875.
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, et al. (2007). Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N. Engl. J. Med. 356: 115-124.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, et al. (2009). Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27: 3584-3590.
15. O'Byrne KJ, Dobbs N, Propper D, Smith K, et al. (1999). Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 353: 1494-1495.
16. Oh SY, Kwon HC, Kim SH, Lee S, et al. (2013). The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer 13: 43.
17. Patard JJ, Pouessel D, Bensalah K and Culine S (2008). Targeted therapy in renal cell carcinoma. World J. Urol. 26: 135-140.
18. Sáenz-López P, Vazquez F, Cozar JM, Carretero R, et al. (2013). VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum. Immunol. 74: 98-103.
19. Salven P, Teerenhovi L and Joensuu H (1997). A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90: 3167-3172.
20. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, et al. (2002). Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 13: 260-264.
21. Vrdoljak E, Rini B, Schmidinger M, Omrcen T, et al. (2013). Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs 24: 431-440.